ArticleNPJ digital medicine2024
Autonomous artificial intelligence for diabetic eye disease increases access and health equity in underserved populations.
Article in NPJ digital medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ethical implications of the use of AI-based technologies for medical image classification systems in screening: a qualitative systematic review.Health technology assessment (Winchester, England) · 2026Pooled it
- Artificial intelligence in diabetic retinopathy: from automated screening to risk-stratified care.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Artificial Intelligence and Eye Disease-Bridging Innovation and Clinical Practice.Journal of clinical medicine · 2026Article
- AI for screening in healthcare: promise and challenges.Abdominal radiology (New York) · 2026Review
- Impact of artificial intelligence on the availability, accessibility, acceptability and quality of ophthalmic disease screening services: a scoping review.The British journal of ophthalmology · 2026Article
- Financial incentives increase uptake and perceived effectiveness of autonomous medical AI, yet patients still seek human reconfirmation.NPJ digital medicine · 2026Article
- Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients.NPJ digital medicine · 2026Article
- Perspectives on healthcare artificial intelligence policy from health equity professionals: findings from an interview study.Frontiers in digital health · 2026Article
- A Perspective on Software Intelligence for Autonomous Transformations in Biomedical Data and Knowledge.Learning health systems · 2026Article
- Clinical warrant in medical LLM evaluation.Frontiers in digital health · 2026Review
- Patient Perspectives on Artificial Intelligence-Based Diabetic Retinopathy Screening at an Urban US Medical Center.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The development and use of chatbots in enhancing health care access for underserved and vulnerable populations: a scoping review.BMC public health · 2025Article
- Evaluating commercial multimodal AI for diabetic eye screening and implications for an alternative regulatory pathway.NPJ digital medicine · 2025Article
- Ten years later: how is AI impacting retina care today?Current opinion in ophthalmology · 2025Article
- A scoping review of artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia and America.NPJ digital medicine · 2025Article
- Cornea Oculomics: A Clinical Blueprint for Extending Corneal Diagnostics and Artificial Intelligence in Systemic Health Insights.Diagnostics (Basel, Switzerland) · 2025Review
- Cost-effectiveness of AI for pediatric diabetic eye exams from a health system perspective.NPJ digital medicine · 2025Article
- Artificial intelligence in ophthalmology: opportunities, challenges, and ethical considerations.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Review
- Detection Rate of Diabetic Retinopathy Before and After Implementation of Autonomous AI-based Fundus Photograph Analysis in a Resource-Limited Area in Belize.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Autonomous Artificial Intelligence for Diabetic Eye Disease Testing Improves Access and Equity in the Pediatric and Adult Populations: The Johns Hopkins Medicine Experience.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
Corrections and comments
- Erratum issued
- Update of
Authors and funding
8 authors.
Funding
Abstract
Diabetic eye disease (DED) is a leading cause of blindness in the world. Annual DED testing is recommended for adults with diabetes, but adherence to this guideline has historically been low. In 2020, Johns Hopkins Medicine (JHM) began deploying autonomous AI for DED testing. In this study, we aimed to determine whether autonomous AI implementation was associated with increased adherence to annual DED testing, and how this differed across patient populations. JHM primary care sites were categorized as "non-AI" (no autonomous AI deployment) or "AI-switched" (autonomous AI deployment by 2021). We conducted a propensity score weighting analysis to compare change in adherence rates from 2019 to 2021 between non-AI and AI-switched sites. Our study included all adult patients with diabetes (>17,000) managed within JHM and has three major findings. First, AI-switched sites experienced a 7.6 percentage point greater increase in DED testing than non-AI sites from 2019 to 2021 (p < 0.001). Second, the adherence rate for Black/African Americans increased by 12.2 percentage points within AI-switched sites but decreased by 0.6% points within non-AI sites (p < 0.001), suggesting that autonomous AI deployment improved access to retinal evaluation for historically disadvantaged populations. Third, autonomous AI is associated with improved health equity, e.g. the adherence rate gap between Asian Americans and Black/African Americans shrank from 15.6% in 2019 to 3.5% in 2021. In summary, our results from real-world deployment in a large integrated healthcare system suggest that autonomous AI is associated with improvement in overall DED testing adherence, patient access, and health equity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.